Clinical Study Data on Traction Based Penis Extenders
The SizeGenetics™ device is manufactured by AndroMedical in Spain and has been the subject of a large number of clincial studies from some of the world's leading sexual health organisations and bodies.
Below you can read the results of the most extensive study on the device which was presented in the First Virtual Sexology and Hispanoamerican Sexual Education Congress in February 2001.
For futher clinical studies on the traction device, you can visit the medically backed page on the SizeGenetics website where a number can be downloaded in PDF format.
Penile enlargement without Surgery with the Andro-Penis
Contents
- Introduction
- Materials and Methods
- Results
- Increase of length in erection
- Increment in length in the flaccid state
- Variability
- The increment in longitude does not depend on the age
- Increment in the perimeter in erection
- Perimeter increment in flaccid state
- Longitude increase in erection state depending on use
- Distribution
- Abbreviations
- Conclusions
- Annex
1. Introduction
When the human tissues are submitted to a force of traction, they react by increasing in size.
The principle of traction is applied in modern medicine, for the generation of new tissue to
cover burn wounds or areas of hair loss (placing a tissular expander underneath the normal
skin ) or for the lenghthening of bones.
In other cultures this principle is applied to lenghten different parts of the body, like the
Giraffe Women of the Paduang tribe in Birmania, or the lenghtening of the lips in certain
African tribes, that use wood to create traction. In India, they hang stones on the penis as a
form of penitence with the resulting enlargement of the organ.
Based on this principle of external traction, the Andro-Penis® was designed. It is able to
exhert a gradual traction force of 600 to 1500 grams.
The device consists of a plastic ring, where the penis is introduced and from where 2 dynamic
metalic rods originate the traction. In the superior part there is a plastic support where a
silicone band holds the glans in place.
Based on our clinical experience the traction device yields the following results:
- An Increase in the length of the penis in erection and flaccidity
- An increase in the perimeter of the penis in erection and flaccidity.
The results will be analyzed statistically to be verified and quantified. See Next.
2. Materials and Methods
Number of patients: 37 patients, ages between 22 and 60 years of age. These men come from
different cities in Spain.
Selection of patients: patients included were healthy men with normal erection capabilities
and without penile surgeries. Patients with penile curvatures or other diseases where
excluded from the studies.
Traction device: The Andro-Penis® penile traction device.
Traction Force: 600 gr during 1st month, 900 gr during 2nd month, 1100 gr during 3th & 4th
month, and 1200 gr during 5th & 6th month.
Usage period: 10 hours a day, during every day of the month for a period of 3-6 months.
3. Results
3.1 Increase of length in erection
The increase in the length of the penis in erection, is relative to the length of time in which the
device is worn. Such growth is lineal as is observed in the chart. This translates in: the longer
the time of use, the more lenght is obtained. The lineal correlation coefficient between time of
use and increase in length in erection is of 0.760 ( p=0.000 )
The average increase in the length of the penis in erection by month is of 0.4726 cm. The
standard deviation is of 0.1329 cm. The confidential interval of 95% is of [0.4283 ; 0.5169] which
indicates a minimal gain in the population of 0.4283 cm/month.
DL erec = - 0.327 + 0.562 x t
This calculation will allow us to estimate the increase in length of the penis in erection, based
on the months of use of the device. There is a 57.7% variance in the increment in longitude,
which is explained by the variance in the duration of treatment ( R2= 0.577 ). The other 42.3% is
due to other differences innate to each individual and not relative to the duration of the
treatment.
3.2 Increment in length in the flaccid state
The increment in length in the flaccid state is relative to the time of usage of the device. Such
an increment is linear as shown in the graph. The longer the device is used, the greater the
increase in length. The coefficient of the linear correlation between the time of usage and the
increment in longitude in the flaccid state is of 0.725 ( p=0.000 ).
The average monthly increment in longitude of the penis in the flaccid state is 0.4834 cm and
the typical deviation is 0.1983 cm. The confidence interval of 95% is of [0.4173 ; 0.5495] and
indicates a minimum increase in the population of 0.4173 cm/month.
Regression line is:
DL flac = - 1.300 + 0.840 x t
This calculation allows us to estimate the increment in longitude in the flaccid state based on
the months in which the device is used. There is a 52.5% variance in the increment in
longitude, which is explained by the variance of the duration of treatment ( R2= 0.525 ). The
other 47.5% is due to other differences innates to the individual and not relative to the duration
of the treatment.
3.3 Variability
The variability in the increment in longitude in erection is different from that of flaccidity,
being the difference in variance significant ( p= 0.003 ) which indicates a greater dispersion of
the increases in length during flaccidity than in erection.
3.4 The increment in longitude does not depend on the age
A very interesting result was that the increment in longitude does not depend on the age of the
patient, since the coefficient of the linear correlation is not significant ( r=0.008, p=0.961). In
other words, the age of the patient does not effect the increment in longitude.
3.5 Increment in the perimeter in erection
In erection, the average increment of the perimeter was of 0.8405 cm and the typical deviation
s=0.5382. The medial growth percentage of the initial perimeter (7.1743%). The growth
interval of 95% of the population studied is (0.611 ;1.0200) which shows a minimal growth
increment of 0.6111 cm.
3.6 Perimeter Increment in flaccid state
The median increment of the perimeter in flaccid state was 0.8405 cm and the typical
deviation s=0.6057. The median percentage of growth was 9.0741%. The confidence interval of
the population studied was (0.6386 ; 1.0425) and shows a minimal perimeter growth increase
of 0.6386 cm.
3.7 Perimeter Increment in flaccid state
Dividing the population studied in four sub groups depending on the usage time of the Andro-
Penis®, we obtain the following results.
Three months usage:
The median longitude increment in erection state was 1.4118, obtaining a median growth of
10.5580% over the initial longitude.The confidence interval of 95% of the studied population
was ( 1.1522; 1.6713) which shows a median minimal growth of 1.1522 cm in three months.
Four months usage:
The median longitude increment in erection state was 1.8462, obtaining a median growth of
14.1113% over the initial longitude. The confidence interval of 95% of the studied population
was (1.5809; 2.1114) which shows a median minimal growth of 1.5809 cm in four months.
Five months usage:
The median longitude increment in erection state was 2.2750, obtaining a median growth of
16.6303% over the initial longitude. The confidence interval of 95% of the population studied
was (1.7656; 2.7844) which shows a median minimal growth of 1.7656 cm in four months.
Six months usage:
The median longitude increment in erection state was 3.3333, obtaining a median growth of
27.5% over the initial longitude. The confidential interval of 95% of the population studied was
(2.8162; 3.8504) which shows a median minimal growth of 2.8162 cm in six months.
The samples corresponding to five and six months are very small, which makes small
intervals and less reliable.
3.8 Distribution
Although the variables considered in the population are not normal, the median samples have
normal distribution since the amount of the sample is greater than 20.
3.9 Abbreviations
| Inc-Long-Erec |
Longitude increment in erection state |
| DL erec |
Change in longitude increment in erection state |
| I.L.ERT |
Longitude increment in erection as a function of the time variable |
| I.L.FLAC |
Longitude increment in flaccid state |
| D.L flac |
Change in longitude increment in flaccid state |
| I.L.FLT |
Longitude increment in flaccid state in function of time |
| Inc-Long-Erec |
Longitude increment in erection state |
| % I Long-Erec |
Longitude increment percentage in erection state. |
4. Conclusions
The use of the traction device ( Andro-Penis® ) will increase the length of the penis, both in the
erectile and flaccid state.
The increase in length, both in erection and flaccidity, is directly proportional to the time of
use.
The increse in length both in erection and flaccidity, does not depend on the natural size of the
patient.
The average growth in length of the penis in cm/month in 95% of the patients was between
0.4283 and 0.5163 in erection, and between 0.4173 and 0.5495 in flaccidity.
The increments of change in length of the penis in erection are more uniform than those in
flaccidity, which tend to be more disparate.
The increment of change in the length of the penis in erection is not relative to the age of the
patient.
The use of the penile traction device will increase the perimeter of the penis, both in erection
and flaccidity.
The average growth in perimeter in cm/month in 95% of the patients was between 0.6111 and
1.0200 in erection, and between 0.6386 and 1.0425 in flaccidity. Treatment was 3-6 months duration.
5. Annex
| Name |
Age |
L-Erec1 |
L-Flac1 |
P-Erec1 |
P-Flac1 |
Month |
L-Erec2 |
L-Flac2 |
P-Erec2 |
P-Flac2 |
| LAA |
60 |
12.0 |
8.0 |
12.0 |
10.0 |
3.0 |
13.5 |
9.0 |
13.5 |
10.5 |
| EAG |
37 |
14.5 |
8.0 |
12.0 |
8.5 |
4.0 |
16.5 |
9.5 |
13.0 |
10.5 |
| VA |
27 |
16.3 |
10.4 |
13.9 |
10.1 |
3.0 |
17.8 |
12.5 |
14.5 |
11.5 |
| EAA |
46 |
14.5 |
10.5 |
12.0 |
10.0 |
6.0 |
17.6 |
15.7 |
13.2 |
11.2 |
| JBV |
25 |
15.0 |
8.0 |
13.0 |
9.0 |
3.0 |
16.6 |
9.5 |
13.3 |
10.5 |
| ABB |
39 |
14.0 |
11.0 |
13.0 |
11.0 |
3.0 |
15.5 |
12.5 |
14.0 |
12.0 |
| CBG |
37 |
12.5 |
6.0 |
12.0 |
9.0 |
4.0 |
14.0 |
8.8 |
12.5 |
9.4 |
| JBL |
25 |
13.7 |
9.0 |
11.5 |
10.0 |
4.0 |
16.3 |
11.5 |
13.5 |
12.0 |
| JCB |
27 |
13.0 |
8.0 |
14.5 |
12.0 |
6.0 |
16.4 |
11.1 |
14.2 |
12.2 |
| JJCA |
33 |
10.5 |
4.9 |
11.0 |
9.5 |
3.0 |
12.0 |
5.5 |
11.5 |
9.5 |
| JCA |
32 |
14.0 |
10.0 |
10.0 |
9.0 |
4.0 |
15.9 |
12.0 |
12.2 |
10.5 |
| ODV |
25 |
16.5 |
9.5 |
13.0 |
9.7 |
3.0 |
18.0 |
11.0 |
13.3 |
10.0 |
| PDS |
22 |
14.4 |
8.3 |
11.0 |
7.8 |
3.0 |
15.8 |
9.0 |
11.6 |
8.3 |
| AGM |
41 |
13.0 |
9.0 |
11.0 |
10.0 |
4.0 |
15.0 |
9.5 |
11.0 |
10.0 |
| MGF |
32 |
12.5 |
5.5 |
12.5 |
10.0 |
4.0 |
14.5 |
8.0 |
13.0 |
10.0 |
| AHM |
44 |
11.5 |
8.0 |
13.0 |
12.0 |
3.0 |
13.0 |
9.5 |
14.0 |
12.0 |
| AAMP |
37 |
12.7 |
7.0 |
10.5 |
7.5 |
3.0 |
14.0 |
9.0 |
11.0 |
9.0 |
| JLMO |
34 |
14.8 |
11.0 |
11.0 |
9.3 |
4.0 |
15.8 |
11.0 |
12.7 |
9.3 |
| JAMV |
41 |
17.0 |
10.0 |
14.0 |
12.5 |
5.0 |
19.6 |
12.3 |
15.0 |
13.5 |
| |
|
| L-Erec1 = Length in Erection Initial |
L-Flac1 = Length in Flaccidity Initial |
| P-Erec1 = Perimeter in Erection Initial |
P-Flac1 = Perimeter in Flaccidity Initial |
| L-Erec2 = Length in Erection Final |
L-Flac2 = Length in Flaccidity Final |
| P-Erec2 = Perimeter in Erection Final |
P-Flac2 = Perimeter in Flaccidity Final |
| |
|
| Name |
Age |
L-Erec1 |
L-Flac1 |
P-Erec1 |
P-Flac1 |
Month |
L-Erec2 |
L-Flac2 |
P-Erec2 |
P-Flac2 |
| FOR |
30 |
12.5 |
7.0 |
10.0 |
9.0 |
5.0 |
14.5 |
11.0 |
11.0 |
10.5 |
| ROM |
28 |
16.0 |
8.5 |
13.0 |
9.0 |
5.0 |
18.0 |
12.5 |
13.5 |
10.5 |
| JPC |
33 |
13.7 |
7.2 |
12.3 |
10.1 |
3.0 |
16.7 |
8.7 |
13.1 |
10.9 |
| JAPG |
29 |
10.0 |
8.0 |
12.0 |
10.0 |
6.0 |
13.5 |
11.5 |
13.0 |
11.0 |
| FPR |
30 |
10.5 |
7.0 |
12.0 |
10.0 |
3.0 |
11.3 |
7.3 |
12.7 |
10.0 |
| JPF |
42 |
13.0 |
7.0 |
13.0 |
10.0 |
3.0 |
14.5 |
8.5 |
13.0 |
10.5 |
| AJRF |
26 |
14.0 |
9.0 |
13.0 |
9.0 |
4.0 |
16.0 |
10.7 |
13.0 |
10.0 |
| ARR |
58 |
11.0 |
7.0 |
11.0 |
9.0 |
3.0 |
12.0 |
8.0 |
12.0 |
10.0 |
| RRG |
25 |
14.5 |
11.0 |
11.0 |
10.0 |
3.0 |
15.0 |
12.4 |
11.7 |
10.8 |
| CSM |
35 |
15.0 |
9.0 |
11.0 |
9.0 |
3.0 |
16.5 |
11.0 |
12.0 |
10.0 |
| ASE |
35 |
12.5 |
7.5 |
11.5 |
9.0 |
4.0 |
14.5 |
9.5 |
12.5 |
10.5 |
| ASPA |
42 |
14.0 |
7.5 |
12.0 |
9.0 |
4.0 |
16.0 |
9.5 |
13.0 |
10.5 |
| SSF |
27 |
14.5 |
7.0 |
14.5 |
8.0 |
3.0 |
15.9 |
8.0 |
15.0 |
8.7 |
| ISB |
22 |
11.5 |
7.5 |
11.0 |
9.5 |
4.0 |
13.5 |
10.2 |
11.3 |
10.3 |
| FT |
53 |
14.5 |
10.0 |
13.0 |
10.0 |
3.0 |
16.0 |
11.5 |
13.5 |
10.5 |
| EVC |
24 |
11.0 |
7.0 |
11.5 |
9.0 |
5.0 |
13.5 |
9.0 |
12.5 |
10.5 |
| PV |
33 |
12.0 |
8.5 |
15.5 |
13.0 |
4.0 |
13.0 |
9.5 |
16.0 |
13.0 |
| JSVS |
32 |
12.0 |
6.0 |
10.5 |
9.0 |
4.0 |
14.0 |
8.5 |
12.5 |
9.5 |
| |
|
| L-Erec1 = Length in Erection Initial |
L-Flac1 = Length in Flaccidity Initial |
| P-Erec1 = Perimeter in Erection Initial |
P-Flac1 = Perimeter in Flaccidity Initial |
| L-Erec2 = Length in Erection Final |
L-Flac2 = Length in Flaccidity Final |
| P-Erec2 = Perimeter in Erection Final |
P-Flac2 = Perimeter in Flaccidity Final |
| |
|
|
